{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T08:39:06Z","timestamp":1794299946176,"version":"4.9.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>AlzeCure Pharma AB is developing novel positive allosteric modulators of Trk-receptors for treatment of Alzheimer\u2019s disease, depression, other psychiatric conditions and other disorders where cognition is impaired. The preceding candidate drug ACD855 was shown to have a too long half-life in humans to allow further development. To de-risk the development of the follow-up compound ACD856, the oral single ascending dose study of ACD856 in humans was preceded by an intravenous microdose study, assessing the elimination half-life in plasma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A phase 0 study with a microdose of ACD856 (0.100\u00a0mg), was conducted in six healthy male subjects all receiving ACD856. Sequentially, a randomized, placebo-controlled, double-blind Phase I single ascending oral dose study (1\u00a0\u2013\u00a0150 mg) was conducted, including 56 healthy subjects. Both studies assessed the safety and tolerability, as well as the PK properties of ACD856 after single dose intravenous and oral administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      ACD856 was well tolerated with no treatment emergent, or dose related adverse events or other safety assessments. In the microdose study, ACD856 exhibited a bi-exponential plasma decline, low distribution volume, low plasma clearance with a half-life of approximately 20\u00a0hours. Orally, ACD856 exhibited rapid absorption, an almost complete bioavailability and a dose proportional increase in exposure. While the C\n                      <jats:sub>max<\/jats:sub>\n                      was lowered and delayed by food intake, the effect on plasma half-life and the overall bioavailability was low. No renal elimination of ACD856 was detected.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The prediction proved accurate demonstrating the value of conducting a microdose study prior to ascending dose studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>NCT05783830 March 24, 2023 (microdose study, retrospectively registered) and NCT05077631 October 14, 2021 (single ascending dose study).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00228-024-03645-1","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T07:02:16Z","timestamp":1707894136000},"page":"717-727","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["ACD856, a novel positive allosteric modulator of Trk receptors, single ascending doses in healthy subjects: Safety and pharmacokinetics"],"prefix":"10.1007","volume":"80","author":[{"given":"Boel","family":"Nilsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Bylund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus M.","family":"Halldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Rother","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Rein-Hedin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"\u00d6nnestam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e4rta","family":"Segerdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,14]]},"reference":[{"issue":"2","key":"3645_CR1","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","volume":"7","author":"GBD 2019 Dementia Forecasting Collaborators","year":"2022","unstructured":"GBD 2019 Dementia Forecasting Collaborators (2022) Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health 7(2):e105\u2013e125. https:\/\/doi.org\/10.1016\/S2468-2667(21)00249-8","journal-title":"Lancet Public Health"},{"issue":"16","key":"3645_CR2","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1503\/cmaj.130451","volume":"185","author":"AC Tricco","year":"2013","unstructured":"Tricco AC, Soobiah C, Berliner B et al (2013) Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis. CMAJ 185(16):1393\u20131401. https:\/\/doi.org\/10.1503\/cmaj.130451","journal-title":"CMAJ"},{"key":"3645_CR3","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol Med 8:595\u2013608. https:\/\/doi.org\/10.15252\/emmm.201606210","journal-title":"EMBO Mol Med"},{"key":"3645_CR4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948","author":"CH van Dyck","year":"2022","unstructured":"van Dyck CH, Swanson CJ, Aisen P et al (2022) Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2212948","journal-title":"N Engl J Med"},{"key":"3645_CR5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen P, Barkhof F et al (2022) Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis 9:197\u2013210. https:\/\/doi.org\/10.14283\/jpad.2022.30","journal-title":"J Prev Alzheimers Dis"},{"key":"3645_CR6","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C et al (2021) Donanemab in early Alzheimer\u2019s disease. N Engl J Med 384:1691\u20131704. https:\/\/doi.org\/10.1056\/NEJMoa2100708","journal-title":"N Engl J Med"},{"key":"3645_CR7","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nrn1078","volume":"4","author":"MV Chao","year":"2003","unstructured":"Chao MV (2003) Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci 4:299\u2013309. https:\/\/doi.org\/10.1038\/nrn1078","journal-title":"Nat Rev Neurosci"},{"key":"3645_CR8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.brainres.2014.10.019","volume":"1621","author":"G Leal","year":"2015","unstructured":"Leal G, Afonso PM, Salazar IL, Duarte CB (2015) Regulation of hippocampal synaptic plasticity by BDNF. Brain Res 1621:82\u2013101. https:\/\/doi.org\/10.1016\/j.brainres.2014.10.019","journal-title":"Brain Res"},{"key":"3645_CR9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/jnen\/64.4.263","volume":"64","author":"SE Counts","year":"2005","unstructured":"Counts SE, Mufson EJ (2005) The role of nerve growth factor receptors in cholinergic basal forebrain degeneration in prodromal Alzheimer disease. J Neuropathology Exp Neurology 64:263\u2013272. https:\/\/doi.org\/10.1093\/jnen\/64.4.263","journal-title":"J Neuropathology Exp Neurology"},{"key":"3645_CR10","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1093\/jnen\/63.6.641","volume":"63","author":"S Peng","year":"2004","unstructured":"Peng S, Wuu J, Mufson EJ et al (2004) Increased proNGF levels in subjects with mild cognitive impairment and mild Alzheimer disease. J Neuropathology Exp Neurology 63:641\u2013649. https:\/\/doi.org\/10.1093\/jnen\/63.6.641","journal-title":"J Neuropathology Exp Neurology"},{"issue":"6","key":"3645_CR11","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1111\/j.1471-4159.2005.03135.x","volume":"93","author":"S Peng","year":"2005","unstructured":"Peng S, Wuu J, Mufson EJ et al (2005) Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer\u2019s disease. J Neurochem 93(6):1412\u20131421. https:\/\/doi.org\/10.1111\/j.1471-4159.2005.03135.x","journal-title":"J Neurochem"},{"issue":"10","key":"3645_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2016.186","volume":"6","author":"SS Jiao","year":"2016","unstructured":"Jiao SS, Shen LL, Zhu C et al (2016) Brain-derived neurotrophic factor protects against tau-related neurodegeneration of Alzheimer\u2019s disease. Transl Psychiatry 6(10):e907. https:\/\/doi.org\/10.1038\/tp.2016.186","journal-title":"Transl Psychiatry"},{"issue":"6","key":"3645_CR13","doi-asserted-by":"publisher","first-page":"1122.e23","DOI":"10.1016\/j.neurobiolaging.2011.11.006","volume":"33","author":"S Kemppainen","year":"2012","unstructured":"Kemppainen S, Rantam\u00e4ki T, Jer\u00f3nimo-Santos A et al (2012) Impaired TrkB receptor signalling contributes to memory impairment in APP\/PS1 mice. Neurobiol Aging 33(6):1122.e23\u201329. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2011.11.006","journal-title":"Neurobiol Aging"},{"issue":"3","key":"3645_CR14","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nm.1912","volume":"15","author":"AH Nagahara","year":"2009","unstructured":"Nagahara AH, Merrill DA, Coppola G et al (2009) Nemetauroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer\u2019s disease. Nat Med 15(3):331\u2013337. https:\/\/doi.org\/10.1038\/nm.1912","journal-title":"Nat Med"},{"issue":"3","key":"3645_CR15","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.nbd.2008.05.012","volume":"31","author":"S Arancibia","year":"2008","unstructured":"Arancibia S, Silhol M, Mouli\u00e8re F et al (2008) Protective effect of BDNF against beta-amyloid induced neurotoxicity in vitro and in vivo in rats. Neurobiol Dis 31(3):316\u2013326. https:\/\/doi.org\/10.1016\/j.nbd.2008.05.012","journal-title":"Neurobiol Dis"},{"key":"3645_CR16","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.3390\/cells10081871","volume":"10","author":"M Dahlstr\u00f6m","year":"2021","unstructured":"Dahlstr\u00f6m M, Madjid N, Nordvall G et al (2021) Identification of novel positive allosteric modulators of neurotrophin receptors for the treatment of cognitive dysfunction. Cells 10:1871. https:\/\/doi.org\/10.3390\/cells10081871","journal-title":"Cells"},{"issue":"3","key":"3645_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1053\/j.jepm.2008.05.013","volume":"17","author":"MA Mitchell","year":"2008","unstructured":"Mitchell MA (2008) Therapeutic review: ponazuril. J Exot Pet Med 17(3):228\u2013229. https:\/\/doi.org\/10.1053\/j.jepm.2008.05.013","journal-title":"J Exot Pet Med"},{"issue":"10","key":"3645_CR18","doi-asserted-by":"publisher","first-page":"103318","DOI":"10.1016\/j.drudis.2022.07.003","volume":"27","author":"G Nordvall","year":"2022","unstructured":"Nordvall G, Forsell P, Sandin S (2022) Neurotrophin-targeted therapeutics: a gateway to cognition and more? Drug Discov Today 27(10):103318. https:\/\/doi.org\/10.1016\/j.drudis.2022.07.003","journal-title":"Drug Discov Today"},{"key":"3645_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-023-06410-x","author":"N Madjid","year":"2023","unstructured":"Madjid N, Lidell V, Nordvall G et al (2023) Antidepressant effects of novel positive allosteric modulators of Trk-receptor mediated signaling \u2013 a potential therapeutic concept? Psychopharmacology, accepted. https:\/\/doi.org\/10.1007\/s00213-023-06410-x","journal-title":"Psychopharmacology, accepted"},{"issue":"2","key":"3645_CR20","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/jvp.12450","volume":"41","author":"ML Stock","year":"2018","unstructured":"Stock ML, Elazab ST, Hsu WH (2018) Review of triazine antiprotozoal drugs used in veterinary Medicine. J Vet Pharmacol Therap 41(2):184\u2013194. https:\/\/doi.org\/10.1111\/jvp.12450","journal-title":"J Vet Pharmacol Therap"},{"key":"3645_CR21","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1001\/jama.284.17.2215","volume":"284","author":"SC Apfel","year":"2000","unstructured":"Apfel SC, Schwartz S, Adornato BT et al (2000) Efficacy and Safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy, a randomized controlled trial. JAMA 284:2215\u20132221. https:\/\/doi.org\/10.1001\/jama.284.17.2215","journal-title":"JAMA"},{"issue":"1","key":"3645_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1053\/gast.2000.8553","volume":"119","author":"B Coulie","year":"2000","unstructured":"Coulie B, Szarka LA, Camilleri M et al (2000) Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans. Gastroenterology 119(1):41\u201350. https:\/\/doi.org\/10.1053\/gast.2000.8553","journal-title":"Gastroenterology"},{"issue":"8","key":"3645_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/annonc\/mdz282","volume":"30","author":"A Drilon","year":"2019","unstructured":"Drilon A (2019) TRK inhibitors in TRK fusion-positive cancers. Ann Oncol\u00a030(Suppl_8):viii23\u2013viii30. https:\/\/doi.org\/10.1093\/annonc\/mdz282","journal-title":"Ann Oncol"},{"issue":"5","key":"3645_CR24","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1159\/000017069","volume":"9","author":"M Eriksdotter J\u00f6nhagen","year":"1998","unstructured":"Eriksdotter J\u00f6nhagen M, Nordberg A, Amberla K et al (1998) Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer\u2019s disease. Dement Geriatr Cogn Disord 9(5):246\u2013257. https:\/\/doi.org\/10.1159\/000017069","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"4","key":"3645_CR25","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","volume":"21","author":"DS Hong","year":"2020","unstructured":"Hong DS, DuBois SG, Kummar S et al (2020) Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials. Lancet Oncol 21(4):531\u2013540. https:\/\/doi.org\/10.1016\/S1470-2045(19)30856-3","journal-title":"Lancet Oncol"},{"issue":"5","key":"3645_CR26","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1212\/01.wnl.0000171978.70849.c5","volume":"65","author":"Z Sahenk","year":"2005","unstructured":"Sahenk Z, Nagaraja HN, McCracken BS et al (2005) NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients. Neurology 65(5):681\u2013689. https:\/\/doi.org\/10.1212\/01.wnl.0000171978.70849.c5","journal-title":"Neurology"},{"issue":"7","key":"3645_CR27","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1212\/wnl.52.7.1427","volume":"52","author":"The BDNF Study Group (Phase III)","year":"1999","unstructured":"The BDNF Study Group (Phase III) et al (1999) A controlled trial of recombinant methionyl human BDNF in ALS. Neurology 52(7):1427\u20131433. https:\/\/doi.org\/10.1212\/wnl.52.7.1427","journal-title":"Neurology"},{"key":"3645_CR28","unstructured":"European Medicines Agency Committee (2009) ICH M3 (R2) Non-clinical safety studies for the conduct of human clinical trials for pharmaceuticals - scientific guideline, step 5 December 1, 2009. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-m3r2-non-clinical-safety-studies-conduct-human-clinical-trials-and-marketing-authorisation-pharmaceuticals-step-5_en.pdf. Accessed 31 May 2023"},{"key":"3645_CR29","unstructured":"Food and Drug Administration (2006) Guidance for industry, investigators, and reviewers. Exploratory IND Studies. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM078933.pdf. Accessed 31 May 2023"},{"key":"3645_CR30","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41573-020-0080-x","volume":"19","author":"T Burt","year":"2020","unstructured":"Burt T, Young G, Lee W et al (2020) Phase 0\/microdosing approaches: time for mainstream application in drug development? Nat Rev Drug Discov 19:801\u2013819","journal-title":"Nat Rev Drug Discov"},{"key":"3645_CR31","unstructured":"Committee for Medicinal Products for Human Use (2017). Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products. European Medicines Agency. EMEA\/CHMP\/SWP\/28367\/07 Rev. 1. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-strategies-identify-and-mitigate-risks-first-human-and-early-clinical-trials-investigational-medicinal-products-revision-1_en.pdf. Accessed 31 May 2023"},{"key":"3645_CR32","unstructured":"National Cancer Institute Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program (2017) Common terminology criteria for adverse events. CTCAE v5.0. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm. Accessed 26 Jan 2023"},{"key":"3645_CR33","doi-asserted-by":"publisher","first-page":"778","DOI":"10.14283\/jpad.2023.89","volume":"10","author":"K \u00d6nnestam","year":"2023","unstructured":"\u00d6nnestam K, Nilsson B, Rother M et al (2023) Safety, tolerability, pharmacokinetics and pharmacodynamics of ACD856, a novel positive allosteric modulator of Trk-receptors, following multiple doses in healthy subjects. J Prev Alzheimers Dis 10:778\u2013789. https:\/\/doi.org\/10.14283\/jpad.2023.89","journal-title":"J Prev Alzheimers Dis"},{"issue":"2","key":"3645_CR34","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/2Fj.1365-2125.2007.03001.x","volume":"65","author":"J Pettersson","year":"2008","unstructured":"Pettersson J, Hindorf U, Persson P et al (2008) Muscular exercise can cause highly pathological liver function tests in healthy men. Br J Clin Pharmacol 65(2):253\u2013259. https:\/\/doi.org\/10.1111\/2Fj.1365-2125.2007.03001.x","journal-title":"Br J Clin Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03645-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03645-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03645-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T02:03:43Z","timestamp":1712541823000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03645-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,14]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["3645"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03645-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3481125\/v1","asserted-by":"object"}]},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,14]]},"assertion":[{"value":"23 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The current clinical studies were conducted in compliance with the study protocol, the International Council for Harmonization Guideline for Good Clinical Practice, all applicable regulatory requirements, and in accordance with the latest revision of the Ethical Principles for Medical Research Involving Human Subjects (the Declaration of Helsinki). The study protocol and all applicable study-related documentation were approved by the Swedish Ethical Review Authority and the Swedish Medical Products Agency. Signed informed consent was obtained from the study participants prior to any study-related activities. Both studies were conducted at the First in Human unit of CTC Clinical Trial Consultants AB, Uppsala, Sweden.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"BN, K\u00d6, and MS are employees of AlzeCure Pharma AB. MR and MMH are paid consultants of AlzeCure Pharma AB. MR represents AlzeCure Pharma AB as a medical expert on multiple safety review committees. ER-H and JB are employees of CTC Clinical Trial Consultants AB, a contract service provider for AlzeCure Pharma AB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}